Opinion
Video
Author(s):
Dr. Hannah Choe reviews data from the AGAVE-201 trial investigating the CSF-1R inhibitor axatilimab, including efficacy, safety, and clinical implications of these data for patients with recurrent or refractory chronic GVHD.
FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation
Revisit the OncLive On Air Episodes From February 2024
FDA Approves Nilotinib Tablets Without Mealtime Restrictions for CML
Mims Expands on the Evaluation of Emavusertib in the TakeAim Leukemia Trial of AML and MDS
Real-World Experience With CAR T Varies From Trials in DLBCL
Revumenib Meets CR/CRh End Point in NPM1+ R/R AML
Dr Caimi on Early Data for LMY-920 in R/R B-Cell NHL
Navigating a “Sea Change” in Frontline Urothelial Carcinoma Treatment
Dr Scalici on Data for IMNN-001 Plus SOC Chemotherapy in Advanced Ovarian Cancer
Dr Lin on the Safety of NKTR-255 in Enhancing Immune Recovery Post-Chemoradiation in Locally Advanced NSCLC